Erectile Dysfunction

Erectile Dysfunction

Maybe you were never previously diagnosed with a hormone deficiency or erectile dysfunction simply because numerous healthcare professionals are not prepared to adequately assess or determine the symptoms that are common with these type of deficiency in men.

If you are feeling that you are getting old and legitimizing that it is just a part of the aging process, there is an answer for you. We are able to efficiently analyze your body's biochemistry, offer real solutions to ensure that your body is performing at its optimum levels.

All through our body's natural aging process, we build up specific deficiencies that happen because of life changes and hereditary genetics. Often times we overlook conditions of hormone imbalances as simply symptoms of old age. Hormones decrease as we age; bio identical hormone treatment replaces the hormones that your body needs to work. Bio identical hormones precisely work the same as the hormones present in the human body.


Shockwave therapy uses energy from acoustic waves to trigger a process called neovascularization in certain parts of the body. Scientists have investigated Low- Intensity Shockwave Therapy to help manage with erectile dysfunction. Blood flow is critical to a man's erections.

Shockwave therapy (SWT) is one of the most effective treatments of calcifications. Acoustic waves cause disruption of the calcified entities and support their resorption and elimination of the body. Shockwave therapy significantly decreases treatment length and offers fast relief in chronic stages.

It helps improve blood flow to the region. This type of therapy has been used to help heart patients, people with kidney stones, and those with fractures and joint inflammation. Recently, scientists have investigated low-intensity shockwave therapy to help men with erectile dysfunction (ED).

Low intensity shockwave therapy to the penis and crura may help men with the following conditions:

Mild to moderate erectile dysfunction (ED)

Both responders and nonresponders to conventional phosphodiesterase type 5